Overview

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

Status:
Unknown status
Trial end date:
2020-07-30
Target enrollment:
0
Participant gender:
All
Summary
Chronic hepatitis C virus infection affects an estimated one hundred and seventy million people around the world with and approximate prevalence 0.2-2 % in the United State of America and European countries.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assiut University
Treatments:
Antiviral Agents
Sofosbuvir
Criteria
Inclusion Criteria:

- Our study proposed for all consented patients complaining from chronic Hepatitis C
virus infection undergoing treatment with antiviral drugs is possible through certain
indications or criteria as follow:

- Patients with chronic Hepatitis C virus who are candidates for Direct Acting Antiviral
Therapy:

- Age is from 18 to 65 years.

Exclusion Criteria:

- Those patients with chronic Hepatitis C virus infection are impossible or
contraindicated to be treated with antiviral drugs as follow: - Geriatrics (> 65 years
of age): - Pediatrics (< 18 years of age): - patients with known hypersensitivity to
any of the components of the antiviral drug.

- Post-Liver Transplant Patients. Ù€Patients with primary haematological abnormalities
not related to chronic hepatitis C virus infection

- Experienced patients (previously failed treatment)